Kyowa Kirin Co., Ltd. (KYKOF)

17,63 0,00 (0,00%) Al cierre: 09:36AM EDT

Kyowa Kirin Co., Ltd.

Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 5974

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Masashi Miyamoto Ph.D.	President, CEO & Representative Director	808,32k	N/A	1959
Mr. Motohiko Kawaguchi	CFO, Managing Executive Officer & Head of Global Finance	N/A	N/A	N/A
Mr. Yutaka Osawa M.B.A.	CCO, Executive VP & Representative Director	492,57k	N/A	1959
Kazuki Nemoto	Head of Global Legal	N/A	N/A	N/A
Satoko Yoshida M.B.A.	Head of Global Corporate Communications	N/A	N/A	N/A
Hiroshi Sonekawa	Managing Executive Officer, VP and Head of Sales & Marketing Division	N/A	N/A	N/A
Wataru Murata M.B.A.	Chief People Officer & Head of Global Human Resources	N/A	N/A	N/A
Mr. Takeyoshi Yamashita Ph.D.	Chief Medical Officer, Senior Managing Executive Officer & Director	N/A	N/A	1961
Yasuo Fujii M.B.A.	Chief Strategy Officer, VP & Managing Executive Officer	N/A	N/A	N/A
Jean-David Rafizadeh-Kabe J.D., M.D.	Head of Global Operational Transformation	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Gobierno corporativo

El ISS Governance QualityScore de Kyowa Kirin Co., Ltd., a día 1 de abril de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 1; Derechos de los accionistas: 4; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.